Table 1 Characteristics of included studies

From: The prognostic value of phosphorylated Akt in breast cancer: a systematic review

Study

Country

Period

N

Stage

ER + (%)

PR + (%)

HER2 + (%)

pAkt + (%)

pAkt detection method

Treatment

Mean FU (year)

Outcome

HR

NOS

Al-Bazz 2009

UK

1994~1997

106

--

59

40

--

21.7

IHC, Ser473

S

5.0

OS, DFS

Uni

5

Aleskandarany 2011

UK

1990~1998

1202

1~3

69

56

13

76.0

IHC, Ser473

S

20.0

DFS

Uni

7

An 2010

Korea

1992~2006

560

1~3

57

49

24

55.2

IHC, Ser473

S

4.9

DFS

Multi

7

Andre 2008

France

1989~1995

752

1~3

86

76

13

15.2

IHC

S

10.0

OS, DFS

Multi

8

Benesch 2010

Germany

1985~1995

160

--

38

52

--

58.1

IHC

S

≥13.0

OS

Uni

6

Capodanno 2009

Italy

1988~1998

72

--

63

--

--

87.5

IHC, Ser473

S/C/R/H

10.0

DFS

Uni

8

Cicenas 2005

Switzerland

-- ~1996

156

--

74

55

39

13.5

IHC, Ser473

--

4.8

DFS

Multi

8

Fabi 2010

Italy

2004~2007

73

4

39

36

100

71.2

IHC, Ser473

C/T

2.0

OS

Uni

5

Gallardo 2012

Spain

--

143

1~4

--

--

100

28.0

IHC

C/T

5.3

OS

Uni

5

Gori 2009

Italy

1999~2006

45

4

49

42

100

51.1

IHC

S/T

1.9

OS

Uni

5

Hartog 2011

Netherland

1996~2005

429

1~3

76

63

7

12.7

IHC, Ser473

C

4.6

DFS

Uni

5

Janssen 2007

Norwegian

1978~1994

125

1~3

53

62

52

43.9

IHC, Ser473

S

11.0

DFS

Uni

7

Kirkegaard 2005

UK

1983~1999

392

--

100

--

45

50.5

IHC, Ser473

C

6.5

OS

Uni

6

Liu 2007

China

1996~2000

130

1~3

100

--

31

46.9

IHC, Ser473

H

5.1

OS, DFS

Multi

8

Nagai 2010

Brazil

--

1026

1~4

67

45

14

48.1

IHC, Ser473

S

10.0

OS, DFS

Uni

6

Perez-Tenorio 2002

Sweden

1984~1996

93

--

76

93

7

53.8

IHC, Ser473

S/H

5.3

DFS

Multi

8

Schmitz 2006

Germany

1989~1996

113

1~3

62

39

26

64.6

IHC, Ser473

S

7.0

OS

Multi

8

Spears 2012

UK

1981~1998

1355

1~3

80

83

13

50.5

IHC, Thr308

S/R

5.0

OS, DFS

Multi

8

Sun 2006

China

1994~1998

260

1~3

--

--

--

50.0

IHC

S

5.0

DFS

Uni

7

Tokunaga 2006

Japan

1991~2002

240

1~3

64

46

25

66.3

IHC, Ser473

S

12.5

DFS

Multi

5

Vestey 2005

UK

1996~2000

95

--

64

--

84

81.1

IHC, Ser473

S

4.3

OS, DFS

Multi

5

Wang 2009, Wang XL 2011

China

1997~2007

110

--

46

46

32

40.9

IHC, Ser473

S

10.0

OS, DFS

Multi*

7

Wang 2010

China

2001~2005

97

1~3

--

--

--

77.3

IHC, Thr308

S

6.5

OS

Uni

6

Wang C 2011

Canada

--

944

1~2

81

--

10

46.7

IHC, Ser473

S

10.4

OS, DFS

Multi

8

Wang AY 2011

China

2001~2005

81

1~3

78

--

--

27.2

IHC

S

>5.0

OS, DFS

Uni

6

Wu 2008

US

1999~2005

141

1~4

--

--

33

50.4

IHC, Ser473

S/C

4.0

DFS

Multi

9

Xia 2004

China

1988~1994

130

1~3

43

50

68

26.2

IHC, Thr308

S

4.0

OS

Uni

7

Yamamoto 2006

Japan

1987~2002

221

1~4

--

--

--

41.2

IHC, Ser473

S/C

5.7

OS, DFS

Multi

7

Yamashita 2008

Japan

1982~1999

278

--

100

--

23

--

IHC, Ser473

S

8.0

OS, DFS

Uni

5

Yonemori 2009

Japan

1999~2006

44

2~3

11

7

100

79.5

IHC

S/C//T

>5.0

DFS

Uni

5

Yu 2010

China

2003~2007

98

1~3

60

56

48

37.8

IHC, Ser473

S

3.0

OS, DFS

Uni

5

Zhou 2004

China

1988~1991

165

--

50

--

32

73.9

IHC, Ser473

S

6.4

DFS

Uni

7

  1. Abbreviations: N = number of patients included for this meta-analysis; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; FU = follow-up; HR = hazard ratio; NOS = Newcastle-Ottawa scale; IHC = immunohistochemistry; S = surgery; OS = overall survival; DFS = disease-free survival; Uni = univariate; Multi = multivariate; C = chemotherapy; R = radiotherapy; H = hormonal therapy; T = trastuzumab.
  2. -- Data not available.
  3. *The analysis on overall survival (Wang 2009) was univariate, while the analysis on disease-free survival (Wang XL 2011) was multivariate.
  4. The analysis on overall survival was univariate, while the analysis on disease-free survival was multivariate.